Appointment comes amid resignation of Marie-France Tschudin from company executive committee.
Effective Sept. 15, Marie-France Tschudin, president, innovative medicines international, chief commercial officer, will be leaving Novartis. In her place, the company has added Patrick Horber with the title of president, international. Currently, Horber works as SVP and president, immunology, AbbVie.
A native of Switzerland with an MD from the University of Zurich, Horber will join Novartis with over 20 years of experience in the biopharma field.
"As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress,” said Horber, in a company press release. “I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”
Reference: Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis. Novartis. September 6, 2023. Accessed September 6, 2023. https://www.novartis.com/news/media-releases/novartis-appoints-patrick-horber-md-president-international-marie-france-tschudin-president-innovative-medicines-international-and-chief-commercial-officer-steps-down-from-executive-committee-novartis
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.